New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
09:05 EDTPFE, GLYCGlycoMimetics presents GMI-1070 data
GlycoMimetics (GLYC) announced that data for its lead clinical drug candidate, rivipansel, or GMI-1070, was highlighted via one oral presentation and one poster at the 8th Annual Sickle Cell Disease Research and Educational Symposium and 37th National Sickle Cell Disease Scientific Meeting. Rivipansel is in clinical trials as a potential therapy for the treatment of vaso-occlusive crisis in people with sickle cell disease. It has previously received both Orphan Drug and Fast Track status for the treatment of VOC from the U.S. Food & Drug Administration and Orphan Product status in the European Union. GlycoMimetics is developing rivipansel in collaboration with Pfizer (PFE).
News For GLYC;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 29, 2015
16:00 EDTPFEOptions Update; May 29, 2015
Subscribe for More Information
08:31 EDTPFEPfizer says FDA approves Rapamune for treatment of LAM
Subscribe for More Information
May 28, 2015
16:34 EDTPFEFDA approves Pfizer's Rapamune to treat LAM
Subscribe for More Information
15:30 EDTPFECellectis in takeover talks with Pfizer named as suitor, FT reports
Subscribe for More Information
10:52 EDTPFEPfizer to host conference call
Subscribe for More Information
09:00 EDTPFEPfizer has 'significant capacity' for additional deals, says JPMorgan
Subscribe for More Information
08:33 EDTPFEPfizer announces $3M grants program to further research in breast cancer
Subscribe for More Information
May 26, 2015
14:07 EDTPFEFDA approves request for updated package insert for Prevnar 13
The FDA approved a request from Pfizer's Wyeth Pharmaceuticals to supplement the biologics license application for Pneumococcal 13-valent Conjugate Vaccine, or Prevnar 13, to update the package insert to include data from the CAPiTA confirmatory efficacy study in adults. Reference Link
08:14 EDTGLYCBoston Biotech Conferences to hold a conference
Subscribe for More Information
May 22, 2015
10:52 EDTPFEJPMorgan says Actavis shares cheap compared to peers
Subscribe for More Information
May 21, 2015
07:37 EDTPFEPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information
May 20, 2015
07:46 EDTPFEDeutsche Bank positive on potential Pfizer, GSK merger
Deutsche Bank analyst Gregg Gilbert believes a large foreign deal for Pfizer (PFE) may make sense and says a buyout of GlaxoSmithKline (GSK) could be "materially" accretive to earnings while improving the company's tax situation over time. Gilbert assumes a $60 per share buyout price for GlaxoSmithKline in a research note this morning titled "Introducing 'PfizerKline'". The stock closed yesterday up 2c to $44.68. Gilbert reiterates a Buy rating on Pfizer with a $41 price target. Shares ended yesterday up 23c to $34.21.
May 19, 2015
09:30 EDTGLYCGlycoMimetics initiates Phase 1/2 clinical trial of GMI-1271
GlycoMimetics announced that the first patient has been dosed in a Phase 1/2 clinical study designed to evaluate the safety, pharmacokinetics and efficacy of GMI-1271, a novel and proprietary E-selectin antagonist in the company’s pipeline, when used in combination with chemotherapy in patients with acute myeloid leukemia. GlycoMimetics is initially exploring the clinical use of the drug candidate in hematologic malignancies following the successful completion of a Phase 1 healthy volunteer study late last year. The company announced last week that the U.S. FDA has granted Orphan Drug designation to GMI-1271 for treatment of AML. This Phase 1/2, open-label multicenter study is designed to determine safety, PK and efficacy of GMI-1271 in combination with chemotherapy in male and female adult patients with AML. Study sites are located in the United States, Australia and Ireland. While the primary objective is to analyze safety, additional endpoints include: mobilization of AML blasts, effect on neutropenia, time to and duration of remission, evaluation of event-free survival and evaluation of the overall survival probability at six- and 12-months. Approximately 77 subjects will be enrolled. The study will include a dose escalation phase followed by expansion of the study once the dose for the Phase 2 portion has been selected.
06:55 EDTPFEGenocea could be takeover target after data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff expects Genocea Biosciences (GNCA) will report positive Phase II GEN-003 post-immunization results late in Q2. GEN-003 is a therapeutic vaccine for genital herpes targeting Herpes Simplex Virus Type 2. Positive GEN-003 data could position Genocea as a potential acquisition target by a larger vaccine player, Tenthoff tells investors today in a research note. Large vaccine makers include Sanofi (SNY), Merck (MRK), GlaxoSmithKline (GSK), Pfizer (PFE) and Novartis (NVS). The analyst reiterates an Overweight rating on Genocea with a $14 price target. Shares of the clinical-stage vaccine developer with a $227M market capitalization closed yesterday up 83c to $10.22.
May 18, 2015
06:58 EDTPFEActavis CEO says chances of Pfizer offer are 'unlikely', Financial Times says
Actavis (ACT) CEO Brent Saunders said the chances of Pfizer (PFE) making an offer are "incredibly unlikely," reports the Financial Times. Saunders said he has heard the gossip that Actavis could become a takeover target for a larger group, but he spends "zero time thinking about it." Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use